Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Glucagon's Effects on Nerves: Glucagon receptors exist throughout the nervous system Activation affects nerve cell metabolism May alter nerve excitability or signal transmission Could disrupt normal sensory processing Supporting Evidence: Dysesthesia only occurs with retatrutide (which has glucagon component) Dose-dependent (higher glucagon activation = more dysesthesia) Not seen in Phase 2 at lower doses (less glucagon effect) Theory 2: Rapid Weight Loss and Nerve Changes Retatrutide produces the fastest, most substantial weight loss of any obesity medication 28.7% at 68 weeks (TRIUMPH-4) and 28.3% at 80 weeks (TRIUMPH-1)
While results vary from person to person, many patients notice: reduction in waist size decreased body fat percentage improved metabolic markers better energy levels reduced visceral fat Fat loss typically occurs gradually, helping support long-term weight management rather than rapid short-term changes
During this initial phase, you may experience mild gastrointestinal symptoms such as reduced appetite, mild nausea, occasional bloating, or changes in bowel habits
Certified Research Peptide Suppliers Access verified suppliers offering research-grade BPC 157 with complete testing documentation
Ivm Health is not affiliated with Novo Nordisk and the compounded semaglutide products available as part of Ivim Healths weight loss programs are not made by Novo Nordisk or any company affiliated with Novo Nordisk.
